SAN FRANCISCO -- Aortic valve regurgitation treated with the investigational JenaValve Trilogy appeared safe and effective in the ALIGN AR trial. The device met the safety benchmark, with a 26.7% rate ...

For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...

Asymptomatic women with moderate-to-severe aortic regurgitation and preserved left ventricular (LV) function managed without surgery had lower survival rates than their male counterparts, although ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — A novel dicrotic notch index identified hemodynamically significant paravalvular aortic ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Along with symptomatic status, elevated indexed left ventricular end-systolic dimension predicted ...

WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...

• The condition of predominant moderate aortic regurgitation could be ameliorated with the rheumatic mitral valve (MV) surgery. What is known and what is new? • During MV surgery, aortic valve ...

NEW YORK, NY—For patients with pure native aortic regurgitation (AR) who are undergoing TAVI, use of devices tailored to treat the AR seems to provide superior outcomes compared with off-label use of ...

Among young adults with aortic regurgitation (AR), those undergoing aortic valve replacement (AVR) before they met standard criteria were more likely to achieve good results from the surgery, a study ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's ...

Some dopamine agonists (pergolide [Permax] or cabergoline [Dostinex]) used to treat Parkinson’s disease may be associated with cardiac-valve regurgitation, based on a case-control study (N Engl J Med.